

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

Brilliant Violet 605(TM) anti-human CD56 (NCAM)

RRID:AB_11142683

Type: Antibody

Proper Citation

BioLegend Cat# 318333, RRID:AB_11142683

Antibody Information

URL: http://antibodyregistry.org/AB_11142683

Proper Citation: BioLegend Cat# 318333, RRID:AB_11142683

Target Antigen: CD56

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-human CD56 (NCAM)

Description: This monoclonal targets CD56

Target Organism: human

Clone ID: Clone HCD56

Antibody ID: AB_11142683

Vendor: BioLegend

Catalog Number: 318333

Alternative Catalog Numbers: 318334

Record Creation Time: 20231110T060622+0000

Record Last Update: 20260829T173409+0000

Ratings and Alerts

- Used for flow cytometry assay by the Human Islet Research Network community.
Contact(s): [Mark Wallet](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for Brilliant Violet 605(TM) anti-human CD56 (NCAM).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Fleming AM, et al. (2026) Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumor. Cell reports, 45(3), 117063.

Pedroza LA, et al. (2025) The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity. Cell reports, 44(1), 115156.

Melo Garcia L, et al. (2025) Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells. Cell reports, 44(1), 115122.

Biederst??dt A, et al. (2025) Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency. Cancer cell.

Cook DR, et al. (2025) Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM. Frontiers in immunology, 16, 1579925.

Shanley M, et al. (2024) Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer cell, 42(8), 1450.